BioCryst Pharmaceuticals (BCRX) Q4 Earnings and Revenues Surpass Estimates

分组1 - BioCryst Pharmaceuticals reported quarterly earnings of $1.12 per share, significantly exceeding the Zacks Consensus Estimate of $0.07 per share, and compared to a loss of $0.13 per share a year ago, representing an earnings surprise of +1,623.08% [1] - The company achieved revenues of $406.56 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 172.17%, and this is a substantial increase from year-ago revenues of $131.53 million [2] - Over the last four quarters, BioCryst has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] 分组2 - The stock has underperformed the market, losing about 3.2% since the beginning of the year, while the S&P 500 has gained 1.5% [3] - The current consensus EPS estimate for the coming quarter is $0.08 on revenues of $158.52 million, and for the current fiscal year, it is $0.29 on revenues of $657.07 million [7] - The Zacks Industry Rank indicates that the Medical - Drugs sector is currently in the bottom 44% of over 250 Zacks industries, suggesting that the industry outlook can materially impact stock performance [8]